Open AccessAssociation of antiretroviral therapy with brain aging changes among HIV-infected adults
Author(s) -
Virawudh Soontornniyomkij,
Anya Umlauf,
Benchawanna Soontornniyomkij,
Ben Gouaux,
Ronald J. Ellis,
Andrew J. Levine,
David J. Moore,
Scott Letendre
Publication year - 2018
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000001927
Subject(s) - putamen , medicine , darunavir , atazanavir , stavudine , odds ratio , emtricitabine , oncology , antiretroviral therapy , immunology , viral load , human immunodeficiency virus (hiv)
Antiretroviral therapy (ART) is currently recommended for all persons living with HIV (PLWH), regardless of their CD4 T-cell count, and should be continued throughout life. Nonetheless, vigilance of the safety of ART, including its neurotoxicity, must continue. We hypothesized that use of certain ART drugs might be associated with aging-related cerebral degenerative changes among PLWH.